ProMIS Neurosciences Q1 net loss $8.2M; PRECISE-AD interim analysis expected early Q3 2026

ProMIS Neurosciences Inc.

2026-Q1 EPS reported -$1.26

Net loss of $8.2M for Q1 2026, vs $7.3M in Q1 2025; cash & equivalents $63.8M as of March 31.
Closed $75.5M PIPE in Feb 2026; up to $100M additional from warrant exercises; funds operations through 2027.
PRECISE-AD Phase 1b fully enrolled (144 participants); blinded 6-month interim analysis anticipated early Q3 2026.
Unblinded 12-month top-line data expected early 2027; subcutaneous formulation development accelerated.
Lead candidate PMN310 selectively targets toxic amyloid-beta oligomers, aiming to improve safety vs plaque-directed antibodies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ProMIS Neurosciences Inc. reported financial results for quarter ended March 31, 2026.

Period: quarter ended March 31, 2026
Result: reported results

Exact text from the filing

reporting its financial condition and financial results as of and for the quarter ended March 31, 2026.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-058967

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.